Recursion Pharmaceuticals 股价在券商评级下调和每股收益不及预期后下跌 11.1%。 Recursion Pharmaceuticals stock dropped 11.1% after brokerage downgrades and a missed EPS.
Recursion Pharmaceuticals 已获得四家券商的“适度买入”共识，1 年平均目标价为 12.67 美元。 Recursion Pharmaceuticals has received a "Moderate Buy" consensus from four brokerages, with an average 1-year price target of $12.67. 然而，最近的评级下调包括 Leerink Partners 将其目标价从 9 美元下调至 8 美元，杰富瑞将其目标价从 8 美元下调至 6 美元。 However, recent downgrades include Leerink Partners lowering its target from $9 to $8, and Jefferies cutting theirs from $8 to $6. 公司股票在这些变化之后下跌了11.1%。 The company's stock dropped 11.1% after these changes. 据Recursion报道,每季度每股收益为0.40美元, 估计不足, 内部人士最近出售了255,682股股票. Recursion reported a quarterly EPS of ($0.40), missing estimates, and insiders sold 255,682 shares recently.